Evidence map›Paper›PMID 35618933›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2022

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.

Francesca Schiano di Cola, Salvatore Caratozzolo, Marco Bolchini, Giulia Ceccardi, Matteo Cortinovis, Paolo Liberini, Alessandro Padovani, Renata Rao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesca Schiano di ColaClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy. francescaschiano@hotmail.it.
Salvatore CaratozzoloClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Marco BolchiniClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Giulia CeccardiClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Matteo CortinovisClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Paolo LiberiniClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Alessandro PadovaniClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Renata RaoClinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalMigraine DisordersAntibodies, MonoclonalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsHumansAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsCGRPDisabilityErenumabMigraineProphylaxis

Identifiers

PMID35618933
PMCPMC9385831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.